Skip to main content
Clinical Trials/NCT04685798
NCT04685798
Terminated
Not Applicable

Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT

Washington University School of Medicine1 site in 1 country8 target enrollmentSeptember 2, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Squamous Cell Carcinoma
Sponsor
Washington University School of Medicine
Enrollment
8
Locations
1
Primary Endpoint
Apparent Diffusion Coefficient Mean (ADCmean)
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The investigators propose a longitudinal study evaluating post-treatment changes in patients with squamous cell carcinoma (SCC) of the neck using an innovative optimized diffusion-weighted imaging (DWI) pulse sequence to identify more accurately recurrent tumors as well as early non-responders to therapy.

Registry
clinicaltrials.gov
Start Date
September 2, 2020
End Date
September 26, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Histologically-proven newly diagnosis or recurrence as indicated by tissue diagnosis of T3 or T4 squamous cell carcinoma of the head and neck
  • Must have had or be scheduled for standard-of-care surgical resection, radiation, and/or chemo-radiation of the diagnosed squamous cell carcinoma of the head and neck
  • At least 18 years of age
  • Patient must be able to understand and willing to sign a written informed consent document.

Exclusion Criteria

  • Contraindications to MRI, including:
  • MRI-incompatible implantable devices
  • severe claustrophobia; and
  • Pregnant and/or breastfeeding, with women of childbearing potential having a negative urine or serum pregnancy test

Outcomes

Primary Outcomes

Apparent Diffusion Coefficient Mean (ADCmean)

Time Frame: 2-3 weeks post-standard of care treatment

* ADC=measure of the magnitude of diffusion (of water molecules) within tissue * The primary tumor, suspicious lesion, and/or area of post-treatment change will be identified in anatomical images \& then outlined in the ADC sequence, excluding areas of cystic change and necrosis. If there are multiple lesions, only the dominant lesion with the lowest ADC will be used for analysis * A histogram analysis method will examine the distribution of ADC values within each region of interest (ROI) * ADCmean will describe distribution of ADC measurements in tumor/non-tumor tissues \& independent sample t-test will compare ADC measurements between the 2 groups

Apparent Diffusion Coefficient Lowest Value in a Tumor (ADCmin)

Time Frame: 2-3 weeks post-standard of care treatment

* ADC=measure of the magnitude of diffusion (of water molecules) within tissue * The primary tumor, suspicious lesion, and/or area of post-treatment change will be identified in anatomical images \& then outlined in the ADC sequence, excluding areas of cystic change and necrosis. If there are multiple lesions, only the dominant lesion with the lowest ADC will be used for analysis * A histogram analysis method will examine the distribution of ADC values within each region of interest (ROI) * ADCmin will describe distribution of ADC measurements in tumor/non-tumor tissues \& independent sample t-test will compare ADC measurements between the 2 groups

Secondary Outcomes

  • Number of Participants That Were Non-responders to Treatment on Both the DWI MRI and the Standard of Care FDG PET/CT(2-3 weeks post-standard of care treatment)

Study Sites (1)

Loading locations...

Similar Trials